Update on paraneoplastic neurologic disorders

Community Oncology

Volumn 7, Issue 5, 2010, Pages 219-224

  Dalmau, Josep ^a   Rosenfeld, Myrna R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

BRAIN ELECTROPHYSIOLOGY; CANCER CHEMOTHERAPY; CANCER SCREENING; CEREBELLUM DEGENERATION; CEREBROSPINAL FLUID EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; EATON LAMBERT SYNDROME; ECHOGRAPHY; ENCEPHALOMYELITIS; GASTROINTESTINAL OBSTRUCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; RETINOPATHY; REVIEW; SENSORY NEUROPATHY;

EID: 77953564650     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70395-3     Document Type: Review

References (44)

1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75: 1135-1140.
2. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56: 715-719.
3. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: a populationbased study. N Engl J Med 1992;326: 363-367.
4. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 1988;111: 577-596.
5. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004;127: 2331-2338.
6. Rees JH, Hain SF, Johnson MR, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001;124: 2223-2231.
7. Mathew RM, Cohen AB, Galetta SL, Alavi A, Dalmau J. Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci 2006;250: 153-155.
8. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 2005;18: 598-603.
9. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004;62: 778-782.
10. Graus F, Dalmau J, Rene R, et al. AntiHu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997;15: 2866-2872.
11. Miyamoto K, Kato T, Watanabe H, Mi-yamoto E, Suzuki S. A case of paraneoplastic syndrome accompanied by two types of cancer. J Neurol Neurosurg Psychiatry 2002;72: 408-409.
12. Buckley C, Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol 2005;1: 22-33.
13. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore) 1992;71: 59-72.
14. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124: 1138-1148.
15. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings, and tumor association in 50 patients. Brain 2000;123: 1481-1494.
16. Tuzun E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007;13: 261-271.
17. Bakheit AM, Kennedy PG, Behan PO. Paraneoplastic limbic encephalitis: clinicopathological correlations. J Neurol Neurosurg Psychiatry 1990;53: 1084-1088.
18. Lacomis D, Khosbin S, Schich RM. MR imaging of paraneoplastic limbic encephalitis. J Comput Assist Tomgr 1990;14: 115-117.
19. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7: 327-340.
20. Blaes F, Strittmatter M, Merkelbach S, et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol 1999;246: 299-303.
21. David YB, Warner E, Levitan M, Sutton DM, Malkin MG, Dalmau JO. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin: a case report. Cancer 1996;78: 2153-2156.
22. Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006;253: 16-20.
23. Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004;6: 55-62.
24. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001;124: 437-443.
25. Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1996;19: 1-47.
26. Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 1992;19: 346-351.
27. Titulaer MJ, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008;201-202: 153-158.
28. O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 1998;50: 88-93.
29. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert Eaton myasthenic syndrome. J Clin Oncol 2008;26: 4276-4281.
30. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86: 44-48.
31. Sakai C, Takagi T, Wakatsuki S. Primary meningeal lymphoma presenting solely with blindness: a report of an autopsy case. Int J Hematol 1996;63: 325-329.
32. Al-Tweigeri T, Magliocco AM, DeCoteau JF. Cortical blindness as a manifestation of hypomagnesemia secondary to cisplatin therapy: case report and review of literature. Gynecol Oncol 1999;72: 120-122.
33. Pomeranz HD, Henson JW, Lessell S. Radiation-associated cerebral blindness. Am J Ophthalmol 1998;126: 609-611.
34. Ko MW, Dalmau J, Galetta SL. Neuro ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008;28: 58-68.
35. Keltner JL, Thirkill CE. Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol 1998;126: 296-302.
36. Jacobson DM, Thirkill CE. Paraneoplastic cone dysfunction: an unusual visual remote effect of cancer. Arch Ophthalmol 1995;113: 1580-1582.
37. Lei B, Bush RA, Milam AH, Sieving PA. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ONresponse of the monkey ERG in vivo. Invest Ophthalmol Vis Sci 2000;41: 262-266.
38. Yu Z, Kryzer TJ, Griesmann GE, Kim KK, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma related autoimmunity. Ann Neurol 2001;49: 146-154.
39. Rotta FT, Bradley WG. Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy. Muscle Nerve 1997;20: 1035-1037.
40. Graus F, Delattre J-Y. Immune modulation of paraneoplastic neurologic disorders. Clin Neurol Neurosurg 1995;97: 112-116.
41. Uchuya M, Graus F, Vega F, Reñé R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996;60: 388-392.
42. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7: 1091-1098.
43. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65: 424-434.
44. Keime-Guibert F, Graus F, Broet P, et al. Clinical outcome of patients with anti-Huassociated encephalomyelitis after treatment of the tumor. Neurology 1999;53: 1719-1723.